COMMUNIQUÉS West-GlobeNewswire

Picard Medical / SynCardia to Present its Next-Generation Emperor Total Artificial Heart Technology at the American College of Cardiology’s Annual Scientific Session
20/03/2026
Poster presentation and conference exhibit will feature early preclinical data on the Company’s fully implantable, autoregulating artificial heart platform TUCSON, Ariz., March 20, 2026 (GLOBE NEWSWIRE) -- Picard [...]
REPRONOVO APPOINTS MARK ALTMEYER AS CHAIRMAN OF THE BOARD
20/03/2026
Lausanne, Switzerland and Copenhagen, Denmark, March 20, 2026 (GLOBE NEWSWIRE) -- REPRONOVO APPOINTS MARK ALTMEYER AS CHAIRMAN OF THE BOARD Biopharma executive with more than 35 years of leadership across C-suite and [...]
The Ensign Group, Inc. Declares Quarterly Dividend of $0.0650 Per Share
20/03/2026
SAN JUAN CAPISTRANO, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign ™ group of companies, which invest in and provide skilled nursing and senior living [...]
Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis
20/03/2026
A retrospective pooled analysis of 1,100 patients demonstrates the Nodify CDT® test’s consistent clinical performance across nodule sizes and patient populations LOUISVILLE, Colo., March 20, 2026 (GLOBE NEWSWIRE) -- [...]
Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer
20/03/2026
SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today [...]
Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer
20/03/2026
Thomas A. Zalewski, a Partner at Day Pitney LLP, appointed Chief Legal Officer and Chief Compliance Officer effective April 2, 2026 Lori J. Braender to remain in a non-executive role as Corporate Secretary after nearly [...]
Sironax Announces Upcoming Poster Presentation on NAMPT Activation
20/03/2026
NAD for Health conference, Copenhagen, March 23-25, 2026 WALTHAM, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Sironax, a global clinical-stage biotechnology company developing transformative therapies for [...]
Scientist Challenges CERN and Industry to Public ‘Known Dataset Test’ to Prove 3D-Flow Can Save Billions and Millions of Lives
20/03/2026
Crosetto Foundation calls for transparency at the 2026 Total Body PET Conference to evaluate technology capable of detecting early-stage cancer currently missed by existing systems DALLAS, March 20, 2026 (GLOBE NEWSWIRE [...]
Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026
20/03/2026
SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world [...]
Foundation Consumer Healthcare Sells Portion of Consumer Health Business
20/03/2026
Company Will Retain Flagship Brand, Plan B One-Step® PITTSBURGH, March 20, 2026 (GLOBE NEWSWIRE) -- Foundation Consumer Healthcare (FCH) announced today that it has entered into a definitive agreement to sell a portion [...]
CapsoVision Announces $14 Million Private Placement Financing
20/03/2026
Reports Preliminary, Unaudited Fourth-Quarter and Full Year 2025 Financial Results SARATOGA, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (the “Company”) (NASDAQ: CV), a commercial-stage medical [...]
WallabyPhenox Announces First U.S. Patient Treated with p48 & p64 MW HPC Flow Modulation Devices in PIANO IDE Trial
20/03/2026
IRVINE, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- WallabyPhenox today announced the successful treatment of the first U.S. patient in the p 48 and p64 MW HPC i n An eurysm O cclusion (PIANO) IDE trial, evaluating the [...]
Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology
20/03/2026
Results from Phase 2 clinical studies, CHAPTER-1 and RAPIDe-1, provide evidence of viability of bradykinin B2 receptor antagonism in management of HAE ZUG, Switzerland, March 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris ( [...]
iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference
20/03/2026
NASHVILLE, Tenn., March 20, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report fourth quarter 2025 financial results after the market closes on [...]
Human Appeal to deliver food aid to thousands of displaced civilians as part of initial response in Lebanon
20/03/2026
Ongoing conflict in the Middle East region has left thousands of families displaced in Lebanon, with an increase in food poverty, poor water sanitation and illness observed MANCHESTER, United Kingdom, March 20, 2026 ( [...]
Galimedix Therapeutics presents strong pharmacokinetic profile of next-generation oral Alzheimer’s candidate at AD/PD™ 2026
20/03/2026
Kensington, MD, USA and Munich/Martinsried, Germany, March 20, 2026 (GLOBE NEWSWIRE) -- Prodrug of oral amyloid beta aggregation modulator demonstrated improved absorption characteristics, leading to substantially [...]
The Cost of Bleeding Revealed: Menstruation costs £20,359 a lifetime, sparking calls for Government action
20/03/2026
New consumer research reveals women and people with cycles spend an average of £20,359 on menstruating in their lifetime More than 1 in 3 (37%) of respondents struggle to afford period products 39% cut back on other [...]
On Match Day, ApolloMD Opens Applications for $5,000 Emergency Medicine Scholarship
20/03/2026
ATLANTA , March 20, 2026 (GLOBE NEWSWIRE) -- As medical students across the country learn where they will train during Match Day, ApolloMD is opening applications for its 2026 Emergency Medicine Scholarship . The annual [...]
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
20/03/2026
Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer The lead asset, SNV4818, currently in a Phase 1/2 [...]

Pages